Brii BiosciencesFRA:7SS -1.50%33 PS Ratio is 32.83 as of Jul. 03, 2026, which is 97% below its 10-year median of 970.00. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 933 Biotechnology companies, Brii Biosciences ranks worse than 75.99% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Brii Biosciences's share price is €0.0985.
Brii Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Hence, Brii Biosciences's PS Ratio for today is 32.83.
Good Sign:
Brii Biosciences Ltd stock PS Ratio (=33.93) is close to 2-year low of 33.93.
The historical rank and industry rank for Brii Biosciences's PS Ratio or its related term are showing as below:
FRA:7SS'
s PS Ratio Range Over the Past 10 Years
Min: 26 Med: 970 Max: 2880
Current: 33.44
During the past 7 years, Brii Biosciences's highest PS Ratio was 2880.00. The lowest was 26.00. And the median was 970.00.
FRA:7SS's PS Ratio is ranked worse than 75.99% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs FRA:7SS: 33.44
Brii Biosciences Ltd revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -29.50% per year.
During the past 7 years, Brii Biosciences's highest 3-Year average Revenue per Share Growth Rate was -29.50% per year. The lowest was -29.50% per year. And the median was -29.50% per year.
Back to Basics: PS Ratio
Brii Biosciences (FRA:7SS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Brii Biosciences PS Ratio Related Terms
Brii Biosciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Brii Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Brii Biosciences's Share Price of today is €0.0985.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Brii Biosciences (FRA:7SS) has a PS Ratio of 32.83 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Brii Biosciences and its competitors. This is 97% below median its historical median of 970.00. Over the past decade, Brii Biosciences' PS Ratio has ranged from 26.00 to 2,880.00. According to the industry distribution chart, Brii Biosciences ranks #709 out of 933 companies in the Biotechnology industry, placing it in the top 76%.
Is Brii Biosciences' PS Ratio too high?
Brii Biosciences' current PS Ratio of 32.83 is 97% below median its 10-year median of 970.00. Over the past 10 years, this metric has ranged from a low of 26.00 to a high of 2,880.00. The Biotechnology industry median PS Ratio is 9.64. Brii Biosciences' value of 32.83 is 240.6% above this industry median. Based on the distribution chart, Brii Biosciences ranks #709 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #709 out of 933 companies for PS Ratio. This places Brii Biosciences in the lower half of its industry. The industry median PS Ratio is 9.64. Brii Biosciences' value of 32.83 is 240.6% above this benchmark. Historically, Brii Biosciences' own PS Ratio has ranged from 26.00 to 2,880.00 over the past decade. While the company's 10-year median is 970.00 vs. the industry median of 9.64, Brii Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brii Biosciences's current PS Ratio of 32.83 is 240.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Brii Biosciences and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brii Biosciences's current PS Ratio is 32.83, which is 97% below median its own 10-year median of 970.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current PS Ratio of 32.83. The current PS Ratio is 32.83, which is 97% below median its 10-year median of 970.00 and 240.6% above the Biotechnology industry median of 9.64. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current PS Ratio is 32.83 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
